FREDERICK, Md.–(BUSINESS WIRE)–BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first time BFI-751 has been administered to humans, as authorized by the Ethics Committees in both Australia and New Zealand.
{iframe}https://www.businesswire.com/news/home/20210525005574/en/BioFactura-Announces-Initiation-of-Phase-I-Study-of-BFI-751-a-Stelara%C2%AE-ustekinumab-Biosimilar{/iframe}